
Pemetrexed-based chemotherapy regimens were more effective as treatment of patients with <em>RET</em>-rearranged non–<a>small</a> cell lung cancer compared with other regimens, according to a multicenter, retrospective study. This treatment also showed similar benefit for various <em>RET</em> fusion types, including <em>KIF5B-<a>RET </a></em>and non-<em>KIF5B-RET</em> fusions.








